Stay updated with breaking news from Rev Oncol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eighteen total abstracts accepted for presentation and publication, including results from four clinical trials evaluating epcoritamab in multiple treatment settings and patient populationsOral presentations highlighting new findings from a clinical trial of epcoritamab in patients with relapsed/refractory (R/R) dif...
Genmab has Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for epcoritamab European Medicines Agency (EMA) has validated Marketing Authorization Application
The Burden of Metastatic Cancer–Induced Bone Pain: A Narrative Review
Company Announcement COPENHAGEN, Denmark; June 30, 2022 – Genmab A/S (Nasdaq: GMAB) today announced its intent to submit a biologics license application...
Epcoritamab demonstrated clinically meaningful efficacy in challenging to treat, highly refractory LBCL patients, including patients previously treated with chimeric antigen receptor (CAR) T-cell therapyTotal patient population achieved overall response rate (ORR) of 63 percent and complete response (CR) of 39 perce...